Mimi Liu, MD
Retina Specialist · Englewood, CONPI 1568469625
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $15,430 of the $22,883 with a category attached, or 67.4%. US Retina LLC accounts for 67.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $7,176 and has fallen 95.5% since, to $322 in 2025.
Across 92 payments — averaging $248.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$15K
- F. Hoffmann-la Roche AG$4K
- AbbVie$985
- Genentech USA, Inc.$608
- Regeneron Healthcare Solutions, Inc.$222
- Alimera Sciences, Inc.$164
- plus $1K from 12 others
Across 251 payments — averaging $8626.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2M
- Roche TCRC, Inc.$155K
- AbbVie$37K
- F. Hoffmann-la Roche AG$13K
What the payments were for
- Speaking & faculty fees$4,47020%
- Grants$830%
- Food & beverage$2,1509%
- Education$7503%
- Ownership interest$15,43067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 4 | $15,430 |
| F. Hoffmann-la Roche AG | 2 | $4,470 |
| AbbVie(2 entities) | 12 | $985 |
| Genentech USA, Inc. | 26 | $608 |
| Regeneron Healthcare Solutions, Inc. | 8 | $222 |
| Alimera Sciences, Inc. | 4 | $164 |
| Hoffmann-la Roche Limited | 1 | $140 |
| Novartis | 8 | $131 |
| Astellas Pharma US Inc | 5 | $125 |
| Coherus Oncology, Inc. | 5 | $120 |
| Biogen | 5 | $105 |
| Eyepoint US, Inc. | 1 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Harrow Eye, LLC | 3 | $62 |
| Neurotech Pharmaceuticals, Inc. | 2 | $56 |
| Genentech, Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $39 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucentis$4,470
- Non-Covered Product$140
- VABYSMO$133
- Iluvien$112
How this compares
$22,883 in reported general payments places this provider in the 85th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 34 | $1,413 |
| Ketorolac Tromethamine | 28 | $1,030 |
| Latanoprost | 50 | $774 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $625 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 25 | $337 |
| Dorzolamide Hcl | 11 | $229 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Englewood
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
- Ashleigh LevisonLafayette$33K
- Moss FenbergDurango$20K
- Lynn HassmanAurora$16K
- Adam MartidisColorado Springs$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.